These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30789856)

  • 21. The study of intestinal absorption and biodistribution in vivo of proton pump inhibitors.
    Shen T; Jiang X; Jin Z; Ji Q; Li C; Li Q; Long H; Qiu W; Wang W; Hou X; You J
    Eur J Pharm Biopharm; 2020 Apr; 149():135-144. PubMed ID: 32007590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of keverprazan for duodenal ulcer: A phase II randomized, double-blind, parallel-controlled trial.
    Tan ND; Liu XW; Liu CX; Li SB; Chen HH; Li X; Wu H; Liao AJ; Zhen YB; Shen PZ; Huo LJ; Liu HL; Shi RH; Zhang BQ; Zhang ZY; Wang JN; Zhan Q; Deng H; Shu X; Tuo BG; Wang QZ; Du SY; Qi LZ; Zhang GX; Peng Q; Wang BM; Ye B; Chen MH; Xiao YL
    J Gastroenterol Hepatol; 2022 Nov; 37(11):2060-2066. PubMed ID: 36068945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
    Langtry HD; Markham A
    Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
    Miwa H; Uedo N; Watari J; Mori Y; Sakurai Y; Takanami Y; Nishimura A; Tatsumi T; Sakaki N
    Aliment Pharmacol Ther; 2017 Jan; 45(2):240-252. PubMed ID: 27891632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Ilaprazole based bismuth-containing quadruple regimen for the first-line treatment of Helicobacter pylori infection: a multicenter, randomized, controlled clinical study].
    Gao W; Cheng H; Hu FL; Lü NH; Xie Y; Sheng JQ; Xu JM; Zhang LX; Zhang L; Chen Y; Zhang ZY; Zhang GX; Cui MH; Yang GB; Gao HJ; Yang L
    Zhonghua Yi Xue Za Zhi; 2012 Aug; 92(30):2108-12. PubMed ID: 23158273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group.
    Thjodleifsson B; Beker JA; Dekkers C; Bjaaland T; Finnegan V; Humphries TJ
    Dig Dis Sci; 2000 May; 45(5):845-53. PubMed ID: 10795744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole Study Group.
    Dekkers CP; Beker JA; Thjodleifsson B; Gabryelewicz A; Bell NE; Humphries TJ
    Aliment Pharmacol Ther; 1998 Aug; 12(8):789-95. PubMed ID: 9726393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Half-dose rabeprazole has an equal efficacy to standard-dose rabeprazole on endoscopic submucosal dissection-induced ulcer.
    Park HJ; Kim HS; Kim BR; Park SY; Hong JH; Jo KW; Kim JW
    Dig Dis Sci; 2013 Apr; 58(4):1054-61. PubMed ID: 23065090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of rabeprazole once daily for acid-related disorders.
    Lanza F; Bardhan KD; Perdomo C; Niecestro R; Barth J
    Dig Dis Sci; 2001 Mar; 46(3):587-96. PubMed ID: 11318537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A double-blind study of pantoprazole and ranitidine in treatment of acute duodenal ulcer. A multicenter trial. European Pantoprazole Study Group.
    Cremer M; Lambert R; Lamers CB; Delle Fave G; Maier C
    Dig Dis Sci; 1995 Jun; 40(6):1360-4. PubMed ID: 7781461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mucosal Healing Effectiveness and Safety of Anaprazole, a Novel PPI, vs. Rabeprazole in Patients With Duodenal Ulcers: A Randomized Double-Blinded Multicenter Phase II Clinical Trial.
    Shu X; Zhu Z; Fu Y; Zhang Z; Wang J; Li X; He S; Fan H; Liu S; Zhang G; Tang J; Huang C; Du Q; Wang X; Xu B; Du Y; Chen Q; Wang B; Chen Y; Duan X; Xie Y; Huo L; Hou X; Lu N
    Front Med (Lausanne); 2021; 8():690995. PubMed ID: 34336894
    [No Abstract]   [Full Text] [Related]  

  • 32. Dose-response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes.
    Hayato S; Hasegawa S; Hojo S; Okawa H; Abe H; Sugisaki N; Munesue M; Horai Y; Ohnishi A
    Eur J Clin Pharmacol; 2012 May; 68(5):579-88. PubMed ID: 22108775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
    Dekkers CP; Beker JA; Thjodleifsson B; Gabryelewicz A; Bell NE; Humphries TJ
    Aliment Pharmacol Ther; 1999 Jan; 13(1):49-57. PubMed ID: 9892879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and tolerability of rabeprazole sodium in subjects aged 12 to 16 years with gastroesophageal reflux disease: an open-label, single- and multiple-dose study.
    James L; Walson P; Lomax K; Kao R; Varughese S; Reyes J;
    Clin Ther; 2007 Sep; 29(9):2082-92. PubMed ID: 18035206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection.
    Fujiwara S; Morita Y; Toyonaga T; Kawakami F; Itoh T; Yoshida M; Kutsumi H; Azuma T
    J Gastroenterol; 2011 May; 46(5):595-602. PubMed ID: 21359522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multicenter prospective observational study of triple therapy with rabeprazole, amoxicillin and metronidazole for Helicobacter pylori in Japan.
    Sugizaki K; Sakata Y; Arai T; Furuhata Y; Iinuma N; Suzuki H
    Intern Med; 2012; 51(22):3103-8. PubMed ID: 23154713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rabeprazole: an update of its use in acid-related disorders.
    Carswell CI; Goa KL
    Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cure of Helicobacter pylori-positive active duodenal ulcer patients: a double-blind, multicentre, 12-month study comparing a two-week dual vs a one-week triple therapy. GISU (Interdisciplinary Group for Ulcer Study).
    Di Mario F; Battaglia F; Dal Bò N; Leandro G; Benedetti E; Bottona E; Caroli A; Costan-Biedo F; De Bastiani R; Germanà B; Andrea Grassi S; Madia D; Marcon V; Marin R; Monica F; Olivieri P; Orzes N; Pilotto A; Ronzani G; Saggioro A; Tafner G
    Dig Liver Dis; 2000 Mar; 32(2):108-15. PubMed ID: 10975783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810).
    Lew EA; Barbuti RC; Kovacs TO; Sytnic B; Humphries TJ; Walsh JH
    Aliment Pharmacol Ther; 1998 Jul; 12(7):667-72. PubMed ID: 9701531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patients have treatment preferences: a multicentre, double-blind, crossover study comparing rabeprazole and omeprazole.
    Johnson M; Guilford S; Libretto SE;
    Curr Med Res Opin; 2002; 18(5):303-10. PubMed ID: 12240793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.